Managing phosphate levels for intensive care patients
Part of Hormones & metabolism clinical trials.
This trial tests a standard way for doctors to manage phosphate levels (a mineral in your blood) in intensive care patients. The goal is to see if a set protocol helps keep your phosphate levels healthy, which could support your overall recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently a patient in one of the intensive care units taking part in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding phosphate granules to feeding tubes can help raise low phosphate levels in ICU patients who are already receiving nutrition through a feeding tube.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
This study creates a database to collect information from patients with rare diseases affecting phosphate metabolism. It aims to improve understanding and care for these conditions.
This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.
This study looks at how breathing and phosphate levels change in the first days of critical illness. It may help doctors understand and manage these changes better.
This study looks at how giving phosphate supplements affects a hormone called FGF23 in patients with low blood phosphate levels. It aims to help understand how the body responds to treatment.
Hear when a new Hypophosphatemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.